MRKR - Marker Therapeutics to Present at Three Upcoming September Investor Conferences

PR Newswire

HOUSTON , Sept. 7, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company will present at three upcoming virtual investor conferences in September.

Conference Details

H.C. Wainwright Annual Global Investment Conference
Company Presenter: Anthony H. Kim , Chief Financial Officer
Date: Monday, September 13, 2021
Time: On-demand beginning at 7:00 a.m. ET

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Company Presenter: Mythili Koneru , M.D., Ph.D., Chief Medical Officer
Date: Wednesday, September 22, 2021
Time: 9:05 a.m. ET

Cantor Fitzgerald Global Healthcare Conference
Fireside Chat
Date: Monday, September 27, 2021
Time: 10:40 a.m. ET

Live webcasts of the presentations will be accessible from the Investors section of the company's website at markertherapeutics.com and will be available for replay following the event.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts .

SOURCE Marker Therapeutics, Inc.